[{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Simvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Mirador Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"23andMe \/ Mirador Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"23andMe \/ Mirador Therapeutics"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"23andMe \/ Almirall","highestDevelopmentStatusID":"4","companyTruncated":"23andMe \/ Almirall"}]

Find Clinical Drug Pipeline Developments & Deals by 23andMe

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Mirador will leverage a set of deidentified genetic and phenotypic data from the 23andMe's proprietary Mirador360 development engine to enable target validation and precision medicine.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 20, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery

                          Sponsor : Mirador Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : 23ME-00610 is a fully humanized monoclonal antibody that is designed to bind to CD200R1. It is under development for clear cell renal cell carcinoma & ovarian cancer.

                          Product Name : 23ME-00610

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 15, 2024

                          Lead Product(s) : 23ME-00610

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : ‘1473 (23ME-01473) is a dual mechanism antibody which works targeting ULBP6 to restore anti-tumor immunity through NK and T cells. It is being evaluated for the treatment of advanced solid tumors.

                          Product Name : ‘1473

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          September 15, 2024

                          Lead Product(s) : 23ME-01473

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : ‘1473 (23ME-01473) is a dual mechanism antibody which works targeting ULBP6 to restore anti-tumor immunity through NK and T cells. It is being evaluated for the treatment of advanced solid tumors.

                          Product Name : ‘1473

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          March 20, 2024

                          Lead Product(s) : 23ME-01473

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : ‘1473 (23ME-01473) is an antibody targeting ULBP6, which suppresses immune activity, currently in preclinical studies for advanced solid tumors.

                          Product Name : ‘1473

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          January 31, 2024

                          Lead Product(s) : 23ME-01473

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : 23ME-00610 is a high-affinity, fully humanized monoclonal antibody that is designed to bind to CD200R1 and prevent the interaction of CD200R1 with CD200. It is under phase 1/2 clinical development for the treatment of advanced neuroendocrine and ovarian ...

                          Product Name : 23ME-00610

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          December 19, 2023

                          Lead Product(s) : 23ME-00610

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : 23ME-00610 is a high-affinity, fully humanized monoclonal antibody that is designed to bind to CD200R1 and prevent the interaction of CD200R1 with CD200. The CD200–CD200R1 axis is an immunological checkpoint that plays a pivotal role in maintenance of ...

                          Product Name : 23ME-00610

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 14, 2023

                          Lead Product(s) : 23ME-00610

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : 23ME-00610 is a, fully humanized mAb that is designed to bind to CD200R1 and prevent the interaction of CD200R1 with CD200. CD200R1 is an inhibitory receptor expressed on T cells and myeloid cells while CD200, ligand of CD200R1, is highly expressed on ce...

                          Product Name : 23ME-00610

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 28, 2023

                          Lead Product(s) : 23ME-00610

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : SLCO1B1 (simvastatin) is a medication in the statin family of drugs, commonly prescribed to lower cholesterol to help reduce the risk of heart attack and stroke.

                          Product Name : SLCO1B1

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 27, 2022

                          Lead Product(s) : Simvastatin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : 23ME-00610 is a high-affinity humanized monoclonal antibody that is designed to bind to the CD200R1 receptor and prevent the interaction of CD200 and CD200R1. The CD200–CD200R1 axis is an immunological checkpoint that plays a pivotal role in maintenanc...

                          Product Name : 23ME-00610

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          July 11, 2022

                          Lead Product(s) : 23ME-00610

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank